# Huayuan Biotech's third-quarter net profit halved as new capacity is repeatedly delayed

> Huayuan Biotech (300401.SZ), a vitamin D3 producer, reported third-quarter 2026 revenue of 278 million yuan, down 7.57% year on year, and net profit attributable to shareholders of 35.8 million yuan, down 50.64%. The company cited higher raw material prices and rising financing costs, and it has postponed several feed-vitamin projects, including vitamin B6, biotin and L-alanine, by about a year.

- Date: 2026-11-21 · published 2026-11-21T06:17:47.725Z
- Category: market · region China · magnitude low
- Page: https://feedsoft.ai/events/112070-huayuan-biotech-s-third-quarter-net-profit-halved-as-new-capacity-is-repeatedly
- Commodities: [Vitamin B6](https://feedsoft.ai/c/VITB6.md), [Vitamin B2](https://feedsoft.ai/c/VITB2.md)

## Why it matters

Delays to vitamin B6 and biotin capacity tighten the supply outlook for these feed additives and keep prices firm. The squeeze on margins from raw material costs also suggests producers may hold back supply, which supports prices.

## Read by commodity

- VITB2: neutral
- VITB6: bullish ▲

## Sources

- zuowenti.com: https://www.zuowenti.com/news/669376.html

---
Data from Feedsoft AI (https://feedsoft.ai/). For information only; not investment advice.
